Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study

PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Yang, Tiequan, Qiu, Guangpin, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/
https://www.ncbi.nlm.nih.gov/pubmed/37691972
http://dx.doi.org/10.2147/JHC.S423684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/
https://www.ncbi.nlm.nih.gov/pubmed/37691972
http://dx.doi.org/10.2147/JHC.S423684

Ejemplares similares